Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
29.99
-1.41 (-4.49%)
At close: Feb 11, 2026, 4:00 PM EST
29.66
-0.33 (-1.10%)
After-hours: Feb 11, 2026, 7:45 PM EST
Tyra Biosciences Employees
Tyra Biosciences had 60 employees as of December 31, 2024. The number of employees increased by 11 or 22.45% compared to the previous year.
Employees
60
Change (1Y)
11
Growth (1Y)
22.45%
Revenue / Employee
n/a
Profits / Employee
-$1,861,400
Market Cap
1.60B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 60 | 11 | 22.45% |
| Dec 31, 2023 | 49 | 11 | 28.95% |
| Dec 31, 2022 | 38 | 13 | 52.00% |
| Dec 31, 2021 | 25 | 12 | 92.31% |
| Jun 30, 2021 | 16 | - | - |
| Mar 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 493 |
| Zymeworks | 263 |
| Biohaven | 256 |
| uniQure | 209 |
| Celldex Therapeutics | 186 |
| Innoviva | 127 |
| Definium Therapeutics | 74 |
| Enliven Therapeutics | 65 |
TYRA News
- 2 months ago - Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer - PRNewsWire
- 3 months ago - Tyra Biosciences Announces Participation at Upcoming Investor Events - PRNewsWire
- 3 months ago - Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights - PRNewsWire
- 6 months ago - Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia - PRNewsWire
- 6 months ago - Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - PRNewsWire
- 7 months ago - Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series - PRNewsWire
- 7 months ago - Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - PRNewsWire
- 8 months ago - Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - PRNewsWire